BRIEF

on VALNEVA (EPA:VLA)

Upbeat Valneva Research Update from First Berlin Equity Research Maintains BUY Rating

Stock price chart of VALNEVA (EPA:VLA) showing fluctuations.

First Berlin Equity Research GmbH has recently released a research update on Valneva SE (ISIN: FR0004056851), reiterating a BUY recommendation with a stable price target of €8.60. This report, curated by analyst Simon Scholes, comes after Valneva announced its final results for 2023, which included positive revisions to its guidance and improved medium-term visibility in several critical areas of operation.

Significantly, Valneva disclosed an 18-month extension of the interest-only period on a $100 million debt, a strategic move that exempts the company from repaying any debt principal in 2024 and 2025. This development is particularly noteworthy as it positions Valneva to achieve sustained positive free cash flow post the anticipated 2027 launch of its Lyme disease vaccine, all without diluting shareholder value. Scholes' report projects confidence in Valneva's financial strategy and operational prospects, bolstering the BUY rating with compelling reasons.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all VALNEVA news